BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Index insights
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Biopharma M&A scorecard
BioWorld 2024 review
BioWorld MedTech 2024 review
BioWorld Science 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Saturday, July 19, 2025
Breaking News: Trump administration impacts continue to roil the life sciences sector
See today's BioWorld Science
Home
» Chengdu Zeling Biomedical Technology patents NLRP3 inflammasome inhibitors
To read the full story,
subscribe
or
sign in
.
Cancer
Chengdu Zeling Biomedical Technology patents NLRP3 inflammasome inhibitors
Oct. 10, 2024
Chengdu Zeling Biomedical Technology Co. Ltd. has identified triazine compounds acting as NLRP3 inflammasome inhibitors.
BioWorld Science
Cancer
Patents
